Peptide News Digest

#Mazdutide

2 stories

Industry · View digest

ADA 2026 Scientific Sessions Three Weeks Out (June 5-8 New Orleans) — Peptide-Specific Slate Anchored on Retatrutide, AstraZeneca Eleglipron, Mazdutide

The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.

Clinical Trials · View digest

Innovent Mazdutide Announces Full ADA 2026 Slate (May 12) — Phase 3 GLORY-2 18.55% Weight Loss + DREAMS-3 vs Semaglutide Head-to-Head

Innovent Biologics announced May 12 that it will present multiple clinical and preclinical results from mazdutide and its next-generation obesity & metabolic pipeline at the 2026 American Diabetes Association Scientific Sessions in New Orleans, June 5-8. Mazdutide is a GLP-1/glucagon dual agonist developed initially for the Chinese market. The Phase 3 GLORY-2 trial in Chinese adults with moderate-to-severe obesity reported a mean 18.55% weight reduction at 60 weeks on 9 mg dosing (vs ~3% placebo); 44% of GLORY-2 patients hit ≥20% body weight loss vs 2.5% on placebo. The Phase 3 head-to-head DREAMS-3 trial in T2D + obesity showed 48% of mazdutide patients hit HbA1c <7% + ≥10% weight loss vs 21% on semaglutide at week 32. The 9 mg dose is under NMPA review for approval in China. Mazdutide is the leading non-Lilly dual GLP-1/glucagon program competing with Boehringer's survodutide and earlier-stage Western programs.